Feedback Plc
Director/PDMR
shareholding
Feedback plc (AIM: FDBK, "Feedback" or the
"Company"), the clinical infrastructure
specialist, announces that on 29 November
2024 the Company was notified of the following Directors'
dealing(s) in the Company's ordinary shares of 1 penny each
("Ordinary Shares"):
Rory Shaw, Non-Executive Chairman,
has purchased 49,261 Ordinary Shares at a price of 20.3 pence per
Ordinary Share.
Philipp Prince, Non-Executive
Director, has purchased 35,469 Ordinary Shares at a price of 20.2
pence per Ordinary Share. He has also sold 20,232 Ordinary Shares
at a price of 19.6 pence per Ordinary Share. This was done to move
the holding from a SIPP to an ISA.
Details of the Ordinary Shares held
are detailed in the table below:
|
Director/ PDMR
|
Position
|
Existing interest in Ordinary Shares
|
Ordinary Shares purchased
|
Ordinary Shares sold
|
Total beneficial interest in Ordinary Shares
|
Total interest in Company's issued share
capital
|
|
Rory Shaw
|
Non-Executive Chairman
|
103,573
|
49,261
|
-
|
152,834
|
0.35%
|
|
Philipp Prince
|
Non-Executive Director
|
24,763
|
35,469
|
20,232
|
40,000
|
0.09%
|
The notification set out below,
provides further details of such dealings:
|
1
|
Details of the person discharging managerial responsibilities
/ person closely associated
|
|
a)
|
Names
|
Rory Shaw
Philipp Prince
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
Non-Executive Chairman
Non-Executive Director
|
|
b)
|
Initial notification
/Amendment
|
Initial notification
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
Feedback plc
|
|
b)
|
LEI
|
213800UGOF2GT2U2RV90
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument, type of instrument
|
Ordinary Shares of 1 penny each
in Feedback plc
|
|
|
|
|
Identification code
|
GB00BJN59X09
|
|
|
|
|
b)
|
Nature of the transaction
|
Purchase of Ordinary
Shares
Purchase of Ordinary Shares /
Sale of Ordinary Shares
|
|
c)
|
Price(s) and volume(s)
|
|
|
|
|
|
|
|
Price(s)
|
Volume(s)
|
|
|
|
|
20.3p
|
49,261
|
|
|
|
|
20.2p / 19.6p
|
35,469 / 20,232
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
d)
|
Aggregated information
|
|
|
|
|
|
- Aggregated volume
|
n/a
|
|
|
|
|
- Price
|
|
|
|
|
|
e)
|
Date of the transaction
|
28 November 2024
29 November 2024
|
|
f)
|
Place of the transaction
|
London Stock Exchange, AIM Market
(XLON)
|
Enquiries:
|
Feedback
plc
Tom Oakley, CEO
Anesh Patel, CFO
|
+44 (0) 20 3997 7634
IR@fbk.com
|
|
|
|
|
Panmure
Liberum Limited (NOMAD and Broker)
Emma Earl/ Mark Rogers (Corporate
Finance)
Rupert Dearden (Corporate Broking)
|
+44 (0)20 7886 2500
|
|
|
|
|
Walbrook PR
Ltd;
|
Tel: 020 7933 8780 or feedbackplc@walbrookpr.com
|
|
Nick Rome/Joe Walker
|
07748 325 236 or 07407 020 470
|
About
Feedback
Feedback plc helps clinical teams to make
better decisions faster for patients. We design products that
enhance clinician access to patient data and to their colleagues.
Our unique approach centres around individual patient episodes,
into which we pull relevant clinical data from hospital systems and
around which we build remote clinical teams for collaboration. As a
result, we produce a digital infrastructure that makes patient data
available to clinicians in multiple settings, in a format that
enables them to meaningfully interact with it, providing
flexibility to clinicians and free movement of patients between
provider settings - clinicians can practice from anywhere and
patients can attend any care provider for treatment, with greater
connectivity across organisations.
Our products Bleepa® and CareLocker® work
together to deliver unparalleled value to our customers. Bleepa® is
our application layer and sits on top of CareLocker® as our data
layer. Bleepa® is a clinician facing platform that displays
clinical results from a patient's CareLocker® at a certified and
regulated quality, that is suitable for clinical use and enables
dialogue on a patient-by-patient basis with colleagues through a
secure, auditable chat interface that links back to the patient
medical record. The CareLocker® data storage model is built around
the patient. Our vision is one where relevant clinical data is
always available to the patient as well as to any care setting that
they may attend - a federated data architecture with the patient as
the tenant.
The Company has a number of growth
opportunities domestically and internationally across a range of
markets including the NHS and private healthcare providers and its
highly scalable Software as a Service ("SaaS")-based model is
expected to provide increasing levels of revenue visibility as the
Company grows its customer base.